CombiGene establishes collaboration with Danish company Zyneyro to revolutionize the treatment of chronic pain

Chronic pain is a global scourge that causes enormous human suffering and astronomical costs to society. The need for new treatments is dramatic.

CombiGene and Zyneyro aim to develop a completely new and revolutionary way to treat pain based on modulation of neuronal signal transmission.

Latest news

Bulletin from the annual general meeting of CombiGene AB (publ)

Read more

New issue of Ingeneious, no 2 2023

Read more

Stock information

Financial reports

Interim report January – March 2023 for CombiGene AB (publ)

Read more

CombiGene AB (publ) publishes annual report for 2022

Read more


COO Peter Ekolind present at Aktiedagen Göteborg (only in Swedish)

CombiGene – the leading Nordic gene therapy company

CombiGene is currently conducting three gene therapy development projects and one peptide project: the pain program COZY consists of one peptide treatment and one gene therapy, which both are based on the same unique mechanism of action; the epilepsy project CG01 is developed for the treatment of drug-resistant focal epilepsy; and the CGT2 project for the treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.

CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the three projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.

The pain program – COZY

The pain program COZY is being developed jointly with the Danish company Zyneyro. The goal is to develop an effective treatment for severe chronic nerve pain. The program consists of two projects – a peptide treatment and a gene therapy treatment (AAV).

The lipodystrophy project – CGT2

The CGT2 project aims to develop a gene therapy treatment for partial lipodystrophy, a rare disease for which effective treatments are currently lacking

The epilepsy project – CG01

The focus is on developing a treatment method for epilepsy patients who cannot be helped by currently available therapies​

In order to prepare CG01 to meet the needs of a global submission the remaining preclinical program will be expanded and, in some parts, complemented with additional studies in collaboration with Spark

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Academic collaborations

Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School. The pain program COZY originates from academic research at Copenhagen University.